UY26696A1 - Método para regular la angiogénesis utilizando proteína ryk - Google Patents
Método para regular la angiogénesis utilizando proteína rykInfo
- Publication number
- UY26696A1 UY26696A1 UY26696A UY26696A UY26696A1 UY 26696 A1 UY26696 A1 UY 26696A1 UY 26696 A UY26696 A UY 26696A UY 26696 A UY26696 A UY 26696A UY 26696 A1 UY26696 A1 UY 26696A1
- Authority
- UY
- Uruguay
- Prior art keywords
- ryk
- anglogenesis
- proteins
- diseases
- protein
- Prior art date
Links
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26696A1 true UY26696A1 (es) | 2001-12-28 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26696A UY26696A1 (es) | 2000-05-10 | 2001-05-08 | Método para regular la angiogénesis utilizando proteína ryk |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (enExample) |
| JP (1) | JP2004527206A (enExample) |
| AR (1) | AR028424A1 (enExample) |
| AU (1) | AU2001261343A1 (enExample) |
| CA (1) | CA2408349A1 (enExample) |
| CO (1) | CO5300464A1 (enExample) |
| DO (1) | DOP2001000164A (enExample) |
| EC (1) | ECSP014068A (enExample) |
| GT (1) | GT200100079A (enExample) |
| PE (1) | PE20011218A1 (enExample) |
| SV (1) | SV2002000442A (enExample) |
| UY (1) | UY26696A1 (enExample) |
| WO (1) | WO2001085789A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516608A (ja) * | 2002-02-06 | 2005-06-09 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | エネルギー恒常性の調節に関与するキナーゼ |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| DK3170005T3 (da) | 2014-07-18 | 2019-07-08 | Sanofi Sa | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer |
| TW202315894A (zh) * | 2021-08-18 | 2023-04-16 | 美國加利福尼亞大學董事會 | 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506969A (ja) * | 1992-05-11 | 1995-08-03 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | レセプタ型チロシンキナーゼ類似の分子 |
| WO1996020403A1 (en) * | 1994-12-23 | 1996-07-04 | Ludwig Institute For Cancer Research | Assay, receptor proteins and ligands |
| ATE321856T1 (de) * | 1998-06-11 | 2006-04-15 | Humane rezeptortyrosinkinase | |
| EP1126869B1 (en) * | 1998-10-28 | 2008-09-03 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using the trk receptor ligands bdnf, nt-3 and nt-4 |
-
2001
- 2001-05-07 AR ARP010102149A patent/AR028424A1/es not_active Application Discontinuation
- 2001-05-07 GT GT200100079A patent/GT200100079A/es unknown
- 2001-05-08 UY UY26696A patent/UY26696A1/es not_active Application Discontinuation
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/ja active Pending
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/es unknown
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/es not_active Application Discontinuation
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Ceased
- 2001-05-09 CO CO01036462A patent/CO5300464A1/es unknown
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/es not_active Application Discontinuation
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001085789A3 (en) | 2002-05-16 |
| AR028424A1 (es) | 2003-05-07 |
| EP1287121A2 (en) | 2003-03-05 |
| CO5300464A1 (es) | 2003-07-31 |
| SV2002000442A (es) | 2002-07-03 |
| CA2408349A1 (en) | 2001-11-15 |
| PE20011218A1 (es) | 2002-02-01 |
| DOP2001000164A (es) | 2002-05-15 |
| GT200100079A (es) | 2001-12-31 |
| AU2001261343A1 (en) | 2001-11-20 |
| ECSP014068A (es) | 2002-02-25 |
| WO2001085789A2 (en) | 2001-11-15 |
| JP2004527206A (ja) | 2004-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28396A1 (es) | Trompas de vegf y usos terapéuticos de las mismas | |
| TR200101307T2 (tr) | Antranilik asit amidler ve ilaç olarak kullanılmaları. | |
| CY1107248T1 (el) | Συντηγμενες πρωτεϊνες | |
| ECSP034548A (es) | Derivados de quinolinona como inhibidores de tirosin quinasa | |
| EA200400482A1 (ru) | Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран | |
| AR039511A1 (es) | Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas | |
| ES2080837T3 (es) | Tratamiento de estados y enfermedades. | |
| SV1995000007A (es) | Derivados del acido micofenolico 5-substituidos. | |
| Philp et al. | Thymosin beta 4 induces hair growth via stem cell migration and differentiation | |
| NO20065027L (no) | Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet | |
| Tak et al. | Oral submucous fibrosis: A review article on etiopathogenesis | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| UY26696A1 (es) | Método para regular la angiogénesis utilizando proteína ryk | |
| DK1343472T3 (da) | Thixotropisk næsespray | |
| ES2162331T3 (es) | Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea. | |
| AR030345A1 (es) | Metodo de tratamiento de desordenes relacionados con angiogenesis | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| ATE390937T1 (de) | Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7 | |
| EP1050309A4 (en) | NEUROTROPHIC FACTOR SECRETION PROMOTERS | |
| ATE283058T1 (de) | Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von dysphorie | |
| UY26649A1 (es) | Proteína que tiene actividad moduladora de angiogenesis | |
| ATE374048T1 (de) | Verwendung von matrixprotein für gesteuerte geweberegenerationen | |
| DE60002552D1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| Sajjad et al. | The The Therapeutic Effects of Autologous Platelet-Rich Plasma Gel on Cutaneous Wound Healing in Rescued Horses: The Effects of Autologous Platelet-Rich Plasma Gel on skin Wound Healing in Horses | |
| ATE302000T1 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20131119 |